NAPLEX (North American Pharmacist Licensure Examination) Practice Exam 2025 - Free NAPLEX Practice Questions and Study Guide

Question: 1 / 1820

What is the primary warning associated with Belatacept?

Increased risk of post-transplant lymphoproliferative disorder

The primary warning associated with Belatacept is an increased risk of post-transplant lymphoproliferative disorder. Belatacept is an immunosuppressive medication that is used in transplant patients to prevent rejection of the transplanted organ. However, it is important to monitor for signs of post-transplant lymphoproliferative disorder, which is a type of cancer that can develop due to the suppression of the immune system. This risk is greater in patients who have previously been infected with the Epstein-Barr virus. The other options are incorrect because while Belatacept may cause liver damage, severe allergic reactions, and acute renal failure, these are not the primary warning associated with this medication. It is important to discuss any potential risks and side effects with a healthcare provider.

Get further explanation with Examzify DeepDiveBeta

May cause severe liver damage

Risk of severe allergic reactions

May lead to acute renal failure

Next Question

Report this question

Download NAPLEX (North American Pharmacist Licensure Examination) Practice Exam PDF Study Guide
Subscribe

Get the latest from Examzify

You can unsubscribe at any time. Read our privacy policy